<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title>Cardiovascular Diabetology</journal-title><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2840-6-29</article-id><article-id pub-id-type="pmid">17919323</article-id><article-id pub-id-type="doi">10.1186/1475-2840-6-29</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>The progesterone receptor PROGINS polymorphism is not related to oxidative stress factors in women with polycystic ovary syndrome</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Karadeniz</surname><given-names>Muammer</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>muammerkaradenis@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Erdogan</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drmerdogan61@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Berdeli</surname><given-names>Afig</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>afig.berdeli@ege.edu.tr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tamsel</surname><given-names>Sadik</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>sadik.tamsel@ege.edu.tr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Saygili</surname><given-names>Fusun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fusun.saygili@ege.edu.tr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Yilmaz</surname><given-names>Candeger</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>candyilmaz@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Internal Disease, Department of Endocrinology and Metabolism, Ege University, Izmir, 35100, Turkey</aff><aff id="I2"><label>2</label>Division of Molecular Medicine Laboratory, Department of Pediatrics, Ege University, Izmir, 35100, Turkey</aff><aff id="I3"><label>3</label>Division of Radiology, Ege University, Izmir, 35100, Turkey</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>5</day><month>10</month><year>2007</year></pub-date><volume>6</volume><fpage>29</fpage><lpage>29</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiab.com/content/6/1/29"/><history><date date-type="received"><day>29</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>5</day><month>10</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Karadeniz et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Karadeniz et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Karadeniz Muammer muammerkaradenis@yahoo.com </dc:author><dc:title> The progesterone receptor PROGINS polymorphism is not related to oxidative stress factors in women with polycystic ovary syndrome </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Cardiovascular Diabetology 6(1): 29-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2840(2007)6:1&#x0003c;29&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2840</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Women with PCOS have been reported to be at increased risk of a number of gynaecological neoplasias, including endometrial, breast, and ovarian cancer. Studies of the possible association of genetic variation in progesterone receptor polymorphism with risk of ovarian and breast cancer have concentrated on a variant known as PROGINS.</p></sec><sec sec-type="methods"><title>Methods</title><p>Ninety-five young women with PCOS and 99 healthy control women were included in our study. All subjects underwent venous blood drawing for complete hormonal assays, lipid profile, glucose, insulin and <italic>PROGINS </italic>polymorphism genetic study.</p></sec><sec><title>Results</title><p>In PROGINS polymorphism results; in both control and the patient groups T1/T1 has been detected in high levels. But for genotype (p = 0.178) and allele (p = 0.555) frequencies both of the groups give similar results. Statistically significant difference has been detected on serum FSH levels for T1/T1 genotype according to T2/T2 genotype.</p></sec><sec><title>Conclusion</title><p>No relation has been detected between the inflammatory and oxidative stress factors, and PROGINS polymorphism alleles. This may be because the PCOS patients are young and their BMI means are normal and their CIMT and oxidative stress markers are like healthy women.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions, which typically occur with chronic anovulation and hyperandrogenism [<xref ref-type="bibr" rid="B1">1</xref>]. Almost 15% of the women at reproductive period complain about PCOS [<xref ref-type="bibr" rid="B2">2</xref>]. Women with PCOS have been reported to be at increased risk of a number of gynaecological neoplasias, including endometrial, breast, and ovarian cancer [<xref ref-type="bibr" rid="B3">3</xref>]. The reproductive abnormalities in PCOS include chronic anovulation, prolonged exposure to oestrogen, progesterone deficiency, and androgen excess, which may contribute to an increased risk for gynaecological cancers in which the hormonal milieu is an important contributor to aetiology and prognosis.</p><p>Oxidative damage has been implicated in the pathogenesis of many chronic progressive diseases, such as cancer, inflammation, and neurodegenerative disorders. Emerging risk factors such as oxidative stress, inflammation and endothelial cell activation are thought to play integral roles in the development of atherosclerotic lesions and cancer [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>In women with PCOS who are anovulatory or oligo-ovulatory, the regulatory roles of progesterone and progesterone withdrawal in the endometrial tissue are suboptimal or absent. In previously studies, heterozygous PROGINS constitution might lead to an over expression of progesterone inducible target genes even at physiologic levels of progesterone [<xref ref-type="bibr" rid="B6">6</xref>]. Moreover, this mechanism may contribute to the process of malignant transformation, atherosclerosis, Oxidative stress, insulin resistance.</p><p>The human progesterone receptor is a single copy gene located on chromosome 11q22-23 [<xref ref-type="bibr" rid="B7">7</xref>]. The actions of progesterone are mediated by two functionally distinct receptor isoforms, PR-A and PR-B, which are expressed from a single gene as a result of transcription from two alternative promoters [<xref ref-type="bibr" rid="B8">8</xref>]. Progesterone acts as a mitogen for breast tissue [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>], and adding progestin's to menopausal oestrogen therapy increases mammographyical density, which is in turn associated with breast cancer risk [<xref ref-type="bibr" rid="B10">10</xref>]. Studies of the possible association of genetic variation in PGR with risk of ovarian [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>] and breast cancer [<xref ref-type="bibr" rid="B14">14</xref>] have concentrated on a variant known as PROGINS. Progesterone is involved in the regulation of VSMC proliferation and modulates the synthesis of proinflammatory proteins such as monocyte chemoattractant protein-1, matrix metalloproteinase, E-selectin, and intercellular adhesion molecule-1 [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>].</p><p>It is not known what impact PROGINS polymorphism may have on the inflammation process of the vasculature. The purpose of present study is to investigate the insulin resistance, inflammatory markers (hs-CRP, fibrinogen) and PROGINS Polymorphisms in young women with PCOS.</p></sec><sec sec-type="methods"><title>Methods</title><p>Informed consent had been obtained before study in all patients and controls. Ninety-five young women (mean age, 24.27 &#x000b1; 5.44 SD years) with PCOS and 99 healthy control women (mean age, 26.41 &#x000b1; 5.65 SD years) were included in our study. PCOS was defined by the Rotterdam PCOS consensus criteria [<xref ref-type="bibr" rid="B17">17</xref>]. In all subjects (patients and controls) baseline plasma concentrations of LH, FSH, total testosterone, 17-hydroxyprogesterone (17-OHP), dihydroepiandrosterone sulphate (DHEA-S), oestradiol, SHBG and prolactin (PRL) were determined during the follicular phase (cycle days 5&#x02013;7) after spontaneous or progestin-induced cycles.</p><p>Patients who had DM, hyperprolactinemia, congenital adrenal hyperplasia (diagnosed with the adrenocorticotropic hormone stimulation test), thyroid disorders, Cushing's syndrome, hypertension, hepatic or renal dysfunction were excluded from the study. Confounding medications, including oral contraceptive agents, hypertensive medications and insulin sensitizing drugs, and those, which may affect the metabolic criteria, were questioned.</p><p>Initially, ninety-nine patients were taken to the study but 4 patients were left voluntarily due to different personal reasons (<italic>genotype success rate = 96,6%</italic>). Similarly, 5 individual of 103 individuals were left the study voluntarily (<italic>genotype success rate = 95,8%</italic>). In all subjects, a clinical examination and an evaluation of hirsutism score by the Ferriman-Gallwey Classification were performed for each woman, a BMI (determined as weight in kg/height in m) were evaluated [<xref ref-type="bibr" rid="B18">18</xref>]. Individuals participating in the control group were the individuals who had laboratorial normal f-testosterone, total &#x02013; testosterone, FSH, LH and basal insulin without acne, alopecia, menstrual disorder, and hirsutism. Healthy young volunteer females matched for age, body mass index (BMI), and allele frequency, were included and considered as the control group. Their healthy state was determined by medical history, physical and pelvic examination, and complete blood chemistry.</p><sec><title>Study protocol</title><p>At study entry, all subjects underwent venous blood drawing for complete hormonal assays, lipid profile, glucose, and insulin and <italic>PROGINS </italic>polymorphism genetic study. All blood samples were obtained in the morning between 08.00 and 09.00 hours after an overnight fasting, and resting in bed during early follicular phase of the spontaneous or P-induced menstrual cycle. During the same visit, all subjects underwent anthropometric measurements including BMI and detail history, systolic and diastolic blood pressure and Doppler ultrasonographic (US) examination for the evaluation of CIMT. In present study, data regarding the metabolic alteration, oxidative stress markers and CIMT outcomes, and the genetic evaluation of <italic>PROGINS </italic>polymorphism will be shown and discussed.</p></sec><sec><title>Biochemical and hormonal assay</title><p>Serum concentrations of hs-CRP were determined by an immunonephelometric assay (N-high-sensitivity CRP; Dade Behring); intra and interassay CV were 1.72 and 2.80%, respectively. Serum total cholesterol, LDL and HDL cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and &#x003b3;-glutamyltransferase (GGT) were measured by Olympus AU 2700 automated analyzer. Plasma insulin concentrations were determined by Immunolite 2000 using two-site chemiluminescent immunometric assay. Serum glucose levels were determined by the glucose oxidase method. Plasma LH, FSH, PRL, oestradiol, progesterone, 17-OHP, testosterone, and dehydroepiandrosterone sulphate were measured by RIA. Insulin resistance was calculated using the homeostasis model assessment insulin resistance index (HOMA-IR) [<xref ref-type="bibr" rid="B19">19</xref>], according to the following formula:</p><p><disp-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" name="1475-2840-6-29-i1" overflow="scroll"><mml:semantics definitionURL="" encoding=""><mml:mrow><mml:mtext>HOMA</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>IR</mml:mtext><mml:mo>=</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mtext>fasting&#x000a0;serum&#x000a0;insulin&#x000a0;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>mU/ml</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x000d7;</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mtext>fasting&#x000a0;plasma&#x000a0;glucose&#x000a0;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>mmol/l</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mn>22.5</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:annotation encoding="MathType-MTEF"> MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=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@86C9@</mml:annotation></mml:semantics></mml:math></disp-formula></p></sec><sec><title>Genetic study</title><p><italic>PROGINS polymorphism </italic>was studied in 95 (genotype success rate 96%) young women with PCOS and 99 healthy women (genotype success rate 94%) control group.</p></sec><sec><title>PROGINS genotyping</title><sec><title>i-DNA purification</title><p>Genomic DNA from patients and healthy controls was extracted from peripheral blood leukocytes using with QIAmp DNA Blood Mini Kits 50 (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. For the PROGINS polymorphism, the following oligonucleotide primers (TIB MOLBIOL Syntheselabor, Berlin-Germany), were used:</p><p>Forward <bold>5'TAT GAG CTA TTT GAG TAA AGC CT-3'</bold></p><p>Reverse &#x02013; 5'-TTC TTG CTA AAT GTC TGT TTT AA-3'</p></sec><sec><title>ii-PCR conditions</title><p>Amplification was carried out on a GeneAmp PCR System 9700(PE Applied Biosystems, Foster City, CA) in a 25 &#x003bc;l reaction mixture in 0.2 ml thin-wall PCR strip tubes (Axygen Scientific, Inc., CA) containing 1 &#x003bc;l genomic DNA solution, GeneAmp Gold Buffer(15 mmol/l Tris-HCl, pH 8.0, 50 mmol/l KCl; PE Applied Biosystems), 1.5 mmol MgCl<sub>2</sub>, 50 &#x003bc;mol/l each of the dGTP, dATp, dTTP and dCTP (Promega, Madison, WI),5 pmol each forward and reverse primers and 1.0 U AmpliTaq Gold polymerase(PE Applied Biosystems). The cycling conditions comprised a hot start at 95&#x000b0;C for 10 min, followed by 35 amplification cycles at 95&#x000b0;C for 30 s, 55&#x000b0;C for 60 s, and 72&#x000b0;C for 45 s, followed by one elongation step at 72&#x000b0;C for 5 min. The PCR products were applied to electrophoretic analysis with the use of a 2% agarose gel Two DNA fragments could be detected: a 185 bp DNA fragment representing 'T1'allele (wild-type) and a 485 bp DNA fragment representing 'T2' allele.</p></sec></sec><sec><title>Methods for plasma MDA, NO, total sulfhydryl group measurements</title><p>All reagents were purchased from Sigma and Merck. MDA was determined by a modified spectrophometric method of Yagi K [<xref ref-type="bibr" rid="B20">20</xref>] using tetrametoxypropan as Standard and BioTek MicroQuant microplate reader. NO was determined by measuring stable NO end-products-nitrite and nitrate levels using Miranda' s spectrophometric method [<xref ref-type="bibr" rid="B21">21</xref>] while total sulfhydryl groups was measured using Ellman's reagent by Sedlak and Lindsay's method [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Radiological measurement</title><p>All examinations were performed by one of the two radiologists experienced in US examinations using an equipment of Sonoline Elegra system (Siemens, Erlangen, Germany) with a 7.5 MHz linear-array transducer. The CIMT measurements were performed on the mid portion of the common carotid artery for intima thickness and total thickness including intima and media measurement.</p></sec><sec><title>Statistical analysis</title><p>SPSS 14.0 for windows (SPSS Inc. Chicago USA) was used for statistical analysis of the results. P &#x0003c; 0.05 values were accepted as statistically significant. The characteristics of the patients with PCOS and the mean plasma glucose, and insulin, dehydroepiandrosterone sulphate, 17&#x003b2;-estradiol, homocysteine, 17-hydroxyprogesterone, prolactin, testosterone levels between the two clinical groups were compared by Student's t test for unpaired data and between and within the different groups (T1/T1, T1/T2, T2/T2) of <italic>PROGINS </italic>polymorphism with the ANOVA.</p><p>Univariate logistic regression analysis was performed in order to show which one of the parameters for which statistically significantly difference was found at Student's t test between patient and control groups was more associated with PCOS. Allelic and genotypic frequencies were determined from observed genotype counts, and the expectations of the Hardy-Weinberg equilibrium were evaluated by &#x003c7;<sup>2 </sup>analysis. Differences in the genotype distribution between different groups were assessed by Pearson's &#x003c7;<sup>2 </sup>test of heterogeneity. All results were expressed as means &#x000b1; SD.</p></sec></sec><sec><title>Results</title><p>Ninety-five PCOS patients and 99 Healthy controls participated in this study. PCOS patients were divided into three sub-groups (T1/T1, T1/T2, T2/T2) according to their PROGINS gene polymorphism. The result of the biochemical, hormonal and oxidative stress parameters and the Carotid intimae media thickness of the PCOS patients sub-groups according to their PROGINS polymorphism is shown in Table <xref ref-type="table" rid="T1">1</xref>. In the patients group no statistically significant differences in HDL &#x02013; cholesterol, LDL &#x02013; cholesterol, total cholesterol, triglyceride, fasting blood glucose, fasting serum insulin, HOMA-IR, prolactine, f-testosterone, total testosterone, estradiol, DHEAS, fibrinogen, hs-CRP and oxidative stress parameters have been detected (Table <xref ref-type="table" rid="T1">1</xref>) (p &#x0003e; 0.05. But a statistically significant difference has been detected on serum FSH levels for T1/T1 genotype according to T2/T2 genotype. In PROGINS polymorphism results; in both control and the patient groups T1/T1 has been detected in high levels (Figure <xref ref-type="fig" rid="F1">1</xref>). But for genotype (p = 0.178) and allele (p = 0.555) frequencies both of the groups give similar results (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>MDA, NO, SH Levels and HOMA-IR Index with PCOS according to The PROGINS genotypes.</p></caption><graphic xlink:href="1475-2840-6-29-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Metabolic and Hormonal Parameters with PCOS According to the PROGINS Genotypes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="4"><bold>PCOS Patients (mean &#x000b1; SD deviation)</bold></td></tr></thead><tbody><tr><td></td><td align="center">T1/T1</td><td align="center">T1/T2</td><td align="center">T2/T2</td><td align="center">P</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center"><bold>Insulin levels (mIU/ml)</bold></td><td align="center">15.3 &#x000b1; 36.11</td><td align="center">15.7 &#x000b1; 19.01</td><td align="center">6.67 &#x000b1; 4.04</td><td align="center">0,39</td></tr><tr><td align="center"><bold>Fasting blood glucose (mg/dL)</bold></td><td align="center">90.8 &#x000b1; 7.7</td><td align="center">91.95 &#x000b1; 11.8</td><td align="center">96.67 &#x000b1; 10</td><td align="center">0,55</td></tr><tr><td align="center"><bold>s-CRP (mg/dl)</bold></td><td align="center">0.33 &#x000b1; 0.3</td><td align="center">0.657 &#x000b1; 1.48</td><td align="center">0.15 &#x000b1; 0.05</td><td align="center">0,39</td></tr><tr><td align="center"><bold>Fibrinogen (mg/dl)</bold></td><td align="center">357.2 &#x000b1; 88.6</td><td align="center">384.2 &#x000b1; 133</td><td align="center">338.6 &#x000b1; 30.4</td><td align="center">0,95</td></tr><tr><td align="center"><bold>Right CIMT (milimeter)</bold></td><td align="center">0.42 &#x000b1; 0.51</td><td align="center">0.424 &#x000b1; 0.43</td><td align="center">0.43 &#x000b1; 0.05</td><td align="center">0,85</td></tr><tr><td align="center"><bold>Left CIMT (milimeter)</bold></td><td align="center">0.429 &#x000b1; 0.52</td><td align="center">0.424 &#x000b1; 0.62</td><td align="center">0.433 &#x000b1; 0.57</td><td align="center">0,85</td></tr><tr><td align="center"><bold>17-OHP (ng/ml)</bold></td><td align="center">5.3 &#x000b1; 2.8</td><td align="center">1.9 &#x000b1; 0.92</td><td align="center">2.2 &#x000b1; 0.8</td><td align="center">0,46</td></tr><tr><td align="center"><bold>HDL &#x02013; Cholesterol (mg/dL)</bold></td><td align="center">56.58 &#x000b1; 15.3</td><td align="center">57.65 &#x000b1; 14.2</td><td align="center">63.6 &#x000b1; 24.77</td><td align="center">0,45</td></tr><tr><td align="center"><bold>LDL &#x02013; Cholesterol (mg/dL)</bold></td><td align="center">117.1 &#x000b1; 33.1</td><td align="center">109.6 &#x000b1; 27.5</td><td align="center">129.0 &#x000b1; 47.6</td><td align="center">0,42</td></tr><tr><td align="center"><bold>Triglycerid (mgl/dL)</bold></td><td align="center">110.8 &#x000b1; 60.1</td><td align="center">143.7 &#x000b1; 88.1</td><td align="center">89.3 &#x000b1; 28.5</td><td align="center">0,42</td></tr><tr><td align="center"><bold>Cholesterol (mg/dL)</bold></td><td align="center">197.1 &#x000b1; 44.2</td><td align="center">194.0 &#x000b1; 37.3</td><td align="center">210.3 &#x000b1; 61.7</td><td align="center">0,84</td></tr><tr><td align="center"><bold>F-testosterone (nmol/Ll)</bold></td><td align="center">2.91 &#x000b1; 1.6</td><td align="center">4.16 &#x000b1; 2.8</td><td align="center">2.5 &#x000b1; 0.7</td><td align="center">0,12</td></tr><tr><td align="center"><bold>FSH (mIU/ml)</bold></td><td align="center">5.72 &#x000b1; 2.16</td><td align="center">4.9 &#x000b1; 1.75</td><td align="center">3.23 &#x000b1; 1.86</td><td align="center">0,04</td></tr></tbody></table><table-wrap-foot><p>If P &#x0003c; 0.05 in chi-square test it is accepted as statistically significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Genotype and Allele Frequencies of the PRP PROGINS Polymorphism in Women With PCOS And Healthy Controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>PRPs</bold></td><td align="center"><bold>PCOS Patients (<italic>n </italic>= 95)</bold></td><td align="center"><bold>Control Groups (n = 99)</bold></td></tr></thead><tbody><tr><td align="left"><bold>Genotypes</bold></td><td></td><td></td></tr><tr><td align="center"><bold>T1/T1</bold></td><td align="center">71 (74.7%)</td><td align="center">67 (67.7%)</td></tr><tr><td align="center"><bold>T1/T2</bold></td><td align="center">21 (22.1%)</td><td align="center">28 (28.3%)</td></tr><tr><td align="center"><bold>T2/T2</bold></td><td align="center">3 (3.2%)</td><td align="center">4 (3.6%)</td></tr><tr><td align="center"><bold>T1/T2 + T2/T2</bold></td><td align="center">24 (25.3%)</td><td align="center">32 (31.9%)</td></tr><tr><td align="left"><bold>Alleles</bold></td><td></td><td></td></tr><tr><td align="center"><bold>T1</bold></td><td align="center">163 (85.8%)</td><td align="center">162 (81.8%)</td></tr><tr><td align="center"><bold>T2</bold></td><td align="center">27 (14.2%)</td><td align="center">36 (18.2%)</td></tr></tbody></table><table-wrap-foot><p><italic>n</italic>, number of patients who could be genotyped successfully.</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>The importance of this study is working on progesterone receptor polymorphism and searching the effects of this polymorphism on the Oxidative stress markers, inflammatory markers and CIMT of the PCOS patients for whom the gynaecological malignancies show increases. Progesterone and estrogen are the main steroid hormones involved in normal reproduction functions. An abnormality may also occur in PGR receptor except for the progesterone itself. Several polymorphisms have been identified in <italic>PGR</italic>; they include S344T, G393G, V660L, H770H, and the <italic>PROGINS </italic>allele [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. The physiological effects of progesterone are completely dependent on the presence of the human <italic>PGR</italic>, a member of the steroid-receptor superfamily of nuclear receptors [<xref ref-type="bibr" rid="B25">25</xref>]. As a consequence of this receptor, PROGINS encodes for a receptor protein with increased stability and increased hormone-induced transcriptional activity [<xref ref-type="bibr" rid="B26">26</xref>]. Functional polymorphisms in genes involved in proliferation and cellular homeostasis may affect the risk for benign and malignant disorders.</p><sec><title>Inflammation and progesterone receptor polymorphism (PROGINS)</title><p>Chronic inflammation has been associated with a risk of atherosclerosis and cancer development. In previously studies have reported an endothelial dysfunction in women with PCOS [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Accumulating evidence also suggests that atherosclerosis represents a chronic inflammatory process and inflammatory markers like CRP and fibrinogen, homocysteine provide an adjunctive method for global assessment of cardiovascular risk [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Recent data also suggest that hs-CRP may directly promote endothelial dysfunction by increasing the synthesis of soluble adhesion molecules, increasing monocyte chemoattractant protein secretion [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. As a result of this study; no difference has been detected on different genotypes of functional progesterone receptor polymorphism (PROGINS) according to hs-CRP and fibrinogen proinflammatory markers, which are important factors for early atherosclerosis in PCOS.</p></sec><sec><title>Insulin resistance and progesterone receptor polymorphism (PROGINS)</title><p>The link of PCOS with insulin resistance was subsequently established by clinical studies characterizing the profound insulin resistance in obese and lean PCOS patients. Insulin resistance, hyperinsulinemia, and beta cell dysfunction are very common in PCOS, but are not required for the diagnosis [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>In PCOS, stimulation of reactive oxygen species (ROS) generation from mononuclear cells (MNCs) by hyperglycaemia may play a role in inflammation through the release of TNF&#x003b1; from circulating MNCs. The oxidative effects of insulin have been demonstrated <italic>in vitro </italic>and in response to both physiological and pharmacological insulin infusions <italic>in vivo </italic>[<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. The estradiol hormone level is high in a menstrual cycle, free radicals produced as a consequence of exercise may be easily removed by inactive women with regular menstrual cycles [<xref ref-type="bibr" rid="B36">36</xref>]. In this study no statistically significant difference has been detected according to plasma glucose, estradiol level, insulin levels and HOMA-IR between the PCOS patients with different functional progesterone receptor polymorphism (PROGINS).</p></sec><sec><title>Oxidative stress parameters and progesterone receptor polymorphism (PROGINS)</title><p>In previously study, did not show a significant correlation between progesterone receptor polymorphism and oxidative system markers in PCOS. It has been reported from experiments in rats that progesterone may also have antioxidant properties in some circumstances [<xref ref-type="bibr" rid="B37">37</xref>]. However, these observations have not been reported in humans.</p><p>In our study, the Oxidative stress markers have been evaluated in the PCOS patients with progesterone receptor polymorphism (PROGINS). In the presence of inflammation MDA and -SH groups increase but "NO" levels decreases in tissues and blood [<xref ref-type="bibr" rid="B38">38</xref>]. Under normal physiological conditions, cellular ROS generation is counterbalanced by the action of antioxidant enzymes and other redox molecules. The balance between <inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2" name="1475-2840-6-29-i2" overflow="scroll"><mml:semantics definitionURL="" encoding=""><mml:mrow><mml:msubsup><mml:mtext>O</mml:mtext><mml:mn>2</mml:mn><mml:mo>&#x02212;</mml:mo></mml:msubsup></mml:mrow><mml:annotation encoding="MathType-MTEF"> MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqqGpbWtdaqhaaWcbaGaeGOmaidabaGaeyOeI0caaaaa@2FDD@</mml:annotation></mml:semantics></mml:math></inline-formula> generation and elimination is important for maintaining proper cellular redox states. A moderate increase in ROS can stimulate cell growth and proliferation [<xref ref-type="bibr" rid="B39">39</xref>]. However, excessive ROS accumulation will lead to cellular injury, such as damage to DNA [<xref ref-type="bibr" rid="B40">40</xref>], protein, and lipid membrane [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. Because of their potential harmful effects, excessive ROS must be promptly eliminated from the cells by a variety of antioxidant defence mechanisms, including important enzymes, such as superoxide dismutase (SOD), catalase, and various peroxidases. Compelling evidence suggests that cancer cells are generally under ROS stress [<xref ref-type="bibr" rid="B43">43</xref>]. Although the precise mechanisms responsible for increased ROS stress in cancer cells have not be defined, the increase in ROS generation is attributed to active cellular metabolic activity under the influence of oncogenic signals and/or to mitochondrial malfunction in cancer cells [<xref ref-type="bibr" rid="B44">44</xref>].</p><p>In our study no statistically significant difference has been detected according to NO, MDA and -SH levels in the patient groups with different PROGINS genotype. It is known that cancer risk (breast, endometrial) in PCOS patients is higher than the healthy women. Our patients are young and the period that they encountered negative metabolic differences is shorter. Differences on metabolic parameters CIMT and oxidative stress markers for these genotypes may occur after a time period.</p><p>In previous studies coronary calcification, as a risk factor of CVD was found to be significantly increased in patients with PCOS in comparison with healthy controls [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. In our study no statistically significant difference has been detected according to f-testosteron, total testosteron and estrogen levels in the patient groups with different PROGINS genotype.</p><p>As a result no relation has been detected between the inflammatory and oxidative stress factors, and PROGINS polymorphism alells. This may be because the patients are young and their BMI means are normal and their CIMT and oxidative stress markers are like healthy women. In the future we planned to study on older PCOS patients and evaluate these parameters for this group.</p></sec></sec><sec><title>Abbreviations</title><p>PCOS &#x02013; polycystic ovary syndrome, BMI &#x02013; body mass index, CI &#x02013; confidence interval, CV &#x02013; coefficient(s) of variation, MLRA-Multipl Logistic Regression Analysis, CVD-cardiovascular disease, DHEAS &#x02013; dehydroepiandrosterone sulphate, E<sub>2</sub>-17&#x003b2;-estradiol, Hcy-homocysteine, 17-OHP-17-hydroxyprogesterone, P &#x02013; progesterone, PRL &#x02013; prolactin, T-testosterone, CIMT-Carotid intima-media thickness, BMI-body mass index, FSH-follicle stimulating hormone, LH-luteinising hormone, HOMA-IR &#x02013; homeostasis model of assessment insulin resistance.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are thankful to Hatice Uluer for her assistance with the statistical evaluation of this study, and the Biofarma Medicine Company for their support.</p><p>In addition we are thankful to Nail Tartaro&#x0011f;lu Endocrinology and Metabolism Laboratory technicians for their technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>RJ</given-names></name></person-group><article-title>A practical approach to the diagnosis of polycystic ovary syndrome</article-title><source>Am J Obstet Gynecol</source><year>2004</year><volume>191</volume><fpage>713</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15467530</pub-id><pub-id pub-id-type="doi">10.1016/j.ajog.2004.04.045</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legro</surname><given-names>RS</given-names></name></person-group><article-title>Polycystic ovary syndrome and cardiovascular disease: a premature association?</article-title><source>Endocr Rev</source><year>2003</year><volume>24</volume><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">12788801</pub-id><pub-id pub-id-type="doi">10.1210/er.2003-0004</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spritzer</surname><given-names>PM</given-names></name><name><surname>Morsch</surname><given-names>DM</given-names></name><name><surname>Wiltgen</surname><given-names>D</given-names></name></person-group><article-title>Polycystic ovary syndrome associated neoplasms</article-title><source>Arq Bras Endocrinol Metabol</source><year>2005</year><volume>49</volume><fpage>805</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16444364</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gadducci</surname><given-names>A</given-names></name><name><surname>Gargini</surname><given-names>A</given-names></name><name><surname>Palla</surname><given-names>E</given-names></name><name><surname>Fanucchi</surname><given-names>A</given-names></name><name><surname>Genazzani</surname><given-names>AR</given-names></name></person-group><article-title>Polycystic ovary syndrome and gynecological cancers: is there a link?</article-title><source>Gynecol Endocrinol</source><year>2005</year><volume>20</volume><fpage>200</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16019362</pub-id><pub-id pub-id-type="doi">10.1080/09513590400021201</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balen</surname><given-names>A</given-names></name></person-group><article-title>Polycystic ovary syndrome and cancer</article-title><source>Hum Reprod Update</source><year>2001</year><volume>7</volume><fpage>522</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11727859</pub-id><pub-id pub-id-type="doi">10.1093/humupd/7.6.522</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>CJ</given-names></name><name><surname>Crapanzano</surname><given-names>JP</given-names></name><name><surname>Watson</surname><given-names>JC</given-names></name><name><surname>Levine</surname><given-names>EA</given-names></name><name><surname>Batzer</surname><given-names>MA</given-names></name></person-group><article-title>PROGINS Alu insertion and human genomic diversity</article-title><source>Mutat Res</source><year>2002</year><volume>25;501</volume><fpage>137</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11934445</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rousseau Merck</surname><given-names>MF</given-names></name><name><surname>Misrahi</surname><given-names>M</given-names></name><name><surname>Loosfelt</surname><given-names>H</given-names></name><name><surname>Milgrom</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name></person-group><article-title>Localization of the human progesterone receptor gene to chromosome 11q22-q23</article-title><source>Hum Genet</source><year>1987</year><volume>77</volume><fpage>280</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">3679212</pub-id><pub-id pub-id-type="doi">10.1007/BF00284486</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Punyadeera</surname><given-names>C</given-names></name><name><surname>Verbost</surname><given-names>P</given-names></name><name><surname>Groothuis</surname><given-names>P</given-names></name></person-group><article-title>Oestrogen and progestin responses in human endometrium</article-title><source>J Steroid Biochem Mol Biol</source><year>2003</year><volume>84</volume><fpage>393</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">12732285</pub-id><pub-id pub-id-type="doi">10.1016/S0960-0760(03)00061-X</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Spicer</surname><given-names>DV</given-names></name><name><surname>Dahmoush</surname><given-names>L</given-names></name><name><surname>Press</surname><given-names>MF</given-names></name></person-group><article-title>Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk</article-title><source>Epidemiol Rev</source><year>1993</year><volume>15</volume><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">8405201</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greendale</surname><given-names>GA</given-names></name><name><surname>Reboussin</surname><given-names>BA</given-names></name><name><surname>Sie</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>HR</given-names></name><name><surname>Olson</surname><given-names>LK</given-names></name><name><surname>Gatewood</surname><given-names>O</given-names></name><name><surname>Bassett</surname><given-names>LW</given-names></name><name><surname>Wasilauskas</surname><given-names>C</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name></person-group><article-title>Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><fpage>262</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10068383</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>Kieback</surname><given-names>DG</given-names></name><name><surname>Carney</surname><given-names>DN</given-names></name><name><surname>Fanning</surname><given-names>M</given-names></name><name><surname>McLinden</surname><given-names>J</given-names></name><name><surname>Headon</surname><given-names>DR</given-names></name></person-group><article-title>A germline TaqI restriction fragment length polymorphismin the progesterone receptor gene in ovarian carcinoma</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>451</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7880723</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Carney</surname><given-names>ME</given-names></name><name><surname>Wiseman</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name></person-group><article-title>Progesterone receptor gene polymorphism and risk for breast and ovarian cancer</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>277</fpage><pub-id pub-id-type="pmid">9683307</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Wenham</surname><given-names>RM</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Calingaert</surname><given-names>B</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Moorman</surname><given-names>PG</given-names></name><name><surname>Bentley</surname><given-names>RC</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Schildkraut</surname><given-names>JM</given-names></name></person-group><article-title>No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2003</year><volume>12</volume><fpage>226</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12646513</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabjani</surname><given-names>G</given-names></name><name><surname>Tong</surname><given-names>D</given-names></name><name><surname>Czerwenka</surname><given-names>K</given-names></name><name><surname>Schuster</surname><given-names>E</given-names></name><name><surname>Speiser</surname><given-names>P</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name></person-group><article-title>Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women</article-title><source>Breast Cancer Res Treat</source><year>2002</year><volume>72</volume><fpage>131</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12038703</pub-id><pub-id pub-id-type="doi">10.1023/A:1014813931765</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brooks-Asplund</surname><given-names>EM</given-names></name><name><surname>Tupper</surname><given-names>CE</given-names></name><name><surname>Daun</surname><given-names>JM</given-names></name><name><surname>Kenney</surname><given-names>WL</given-names></name><name><surname>Cannon</surname><given-names>JG</given-names></name></person-group><article-title>Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women</article-title><source>Cytokine</source><year>2002</year><volume>19</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">12297113</pub-id><pub-id pub-id-type="doi">10.1006/cyto.2002.1963</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>PJ</given-names></name><name><surname>Sutherland</surname><given-names>WH</given-names></name><name><surname>Allum</surname><given-names>AR</given-names></name><name><surname>de Jong</surname><given-names>SA</given-names></name><name><surname>Jones</surname><given-names>SD</given-names></name></person-group><article-title>Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with type 2 diabetes</article-title><source>Diabet Med</source><year>2002</year><volume>19</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">12358873</pub-id><pub-id pub-id-type="doi">10.1046/j.1464-5491.2002.00808.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><collab>The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group</collab></person-group><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><fpage>41</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14688154</pub-id><pub-id pub-id-type="doi">10.1093/humrep/deh098</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferriman</surname><given-names>D</given-names></name><name><surname>Gallwey</surname><given-names>JD</given-names></name></person-group><article-title>Clinical assessment of body hair growth in women</article-title><source>J Clin Endocrinol Metab</source><year>1961</year><volume>21</volume><fpage>1440</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">13892577</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">3899825</pub-id><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id></citation></ref><ref id="B20"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Armstrong D</surname></name></person-group><article-title>Lipid peroxides in hepatic, gastrointestinal and pancreatic diseases</article-title><source>Free radicals in Diagnostic Medicine</source><year>1994</year><publisher-name>New York, NY, Plenum Press</publisher-name><fpage>165</fpage><lpage>169</lpage></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>KM</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name></person-group><article-title>A rapid, simple spectrophometric method for simultaneous detection of nitrate and nitrite</article-title><source>Nitric Oxide</source><year>2001</year><volume>5</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11178938</pub-id><pub-id pub-id-type="doi">10.1006/niox.2000.0319</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sedlak</surname><given-names>J</given-names></name><name><surname>Lindsay</surname><given-names>RH</given-names></name></person-group><article-title>Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent</article-title><source>Anal Biochem</source><year>1968</year><volume>25</volume><fpage>192</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">4973948</pub-id><pub-id pub-id-type="doi">10.1016/0003-2697(68)90092-4</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Risch</surname><given-names>HA</given-names></name><name><surname>Bale</surname><given-names>AE</given-names></name><name><surname>Beck</surname><given-names>PA</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>PGR +331 A/G and increased risk of epithelial ovarian cancer</article-title><source>Cancer EpidemiolBiomarkers Prev</source><year>2006</year><volume>15</volume><fpage>1738</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0272</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>KM</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>Ho</surname><given-names>SM</given-names></name></person-group><article-title>Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>5722</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10318951</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.10.5722</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>SM</given-names></name><name><surname>Coughlan</surname><given-names>SJ</given-names></name><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>Garrett</surname><given-names>E</given-names></name><name><surname>Kieback</surname><given-names>DG</given-names></name><name><surname>Carney</surname><given-names>DN</given-names></name><name><surname>Headon</surname><given-names>DR</given-names></name></person-group><article-title>Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion</article-title><source>Cancer Res</source><year>1995</year><volume>1;55</volume><fpage>2743</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7796397</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agoulnik</surname><given-names>IU</given-names></name><name><surname>Tong</surname><given-names>XW</given-names></name><name><surname>Fischer</surname><given-names>DC</given-names></name><name><surname>Korner</surname><given-names>K</given-names></name><name><surname>Atkinson</surname><given-names>NE</given-names></name><name><surname>Edwards</surname><given-names>DP</given-names></name><name><surname>Headon</surname><given-names>DR</given-names></name><name><surname>Weigel</surname><given-names>NL</given-names></name><name><surname>Kieback</surname><given-names>DG</given-names></name></person-group><article-title>A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>6340</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15579801</pub-id><pub-id pub-id-type="doi">10.1210/jc.2004-0114</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohshima</surname><given-names>H</given-names></name><name><surname>Tatemichi</surname><given-names>M</given-names></name><name><surname>Sawa</surname><given-names>T</given-names></name></person-group><article-title>Chemical basis of inflammation-induced carcinogenesis</article-title><source>Arch Biochem Biophys</source><volume>417</volume><fpage>3</fpage><lpage>11</lpage><comment>2003 Sep 1</comment><pub-id pub-id-type="pmid">12921773</pub-id><pub-id pub-id-type="doi">10.1016/S0003-9861(03)00283-2</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Wargovich</surname><given-names>MJ</given-names></name></person-group><article-title>Inflammation, cancer, and targets of ginseng</article-title><source>J Nutr</source><year>2007</year><volume>137</volume><fpage>183S</fpage><lpage>5S</lpage><pub-id pub-id-type="pmid">17182823</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickerton</surname><given-names>AS</given-names></name><name><surname>Clark</surname><given-names>N</given-names></name><name><surname>Meeking</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>KM</given-names></name><name><surname>Crook</surname><given-names>M</given-names></name><name><surname>Lumb</surname><given-names>P</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>MH</given-names></name></person-group><article-title>Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><fpage>151</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15677534</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2003.015271</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Refsum</surname><given-names>H</given-names></name><name><surname>Ueland</surname><given-names>PM</given-names></name><name><surname>Nygard</surname><given-names>O</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name></person-group><article-title>Homocysteine and cardiovascular disease</article-title><source>Annu Rev Med</source><year>1998</year><volume>49</volume><fpage>31</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9509248</pub-id><pub-id pub-id-type="doi">10.1146/annurev.med.49.1.31</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>DW</given-names></name></person-group><article-title>Homocysteine and vitamins in cardiovascular disease</article-title><source>Clin Chem</source><year>1998</year><volume>44</volume><fpage>1833</fpage><lpage>1843</lpage><pub-id pub-id-type="pmid">9702993</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deepa</surname><given-names>R</given-names></name><name><surname>Velmurugan</surname><given-names>K</given-names></name><name><surname>Arvind</surname><given-names>K</given-names></name><name><surname>Sivaram</surname><given-names>P</given-names></name><name><surname>Sientay</surname><given-names>C</given-names></name><name><surname>Uday</surname><given-names>S</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group><article-title>Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance &#x02013; the Chennai Urban Rural Epidemiology Study (CURES)</article-title><source>Metabolism</source><year>2006</year><volume>55</volume><fpage>1232</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16919544</pub-id><pub-id pub-id-type="doi">10.1016/j.metabol.2006.05.008</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name></person-group><article-title>Insulin resistance in PCOS</article-title><source>Endocrine</source><year>2006</year><volume>30</volume><fpage>13</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17185787</pub-id><pub-id pub-id-type="doi">10.1385/ENDO:30:1:13</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rifici</surname><given-names>VA</given-names></name><name><surname>Schneider</surname><given-names>SH</given-names></name><name><surname>Khachadurian</surname><given-names>AK</given-names></name></person-group><article-title>Stimulation of low-density lipoprotein oxidation by insulin and insulin like growth factor I</article-title><source>Atherosclerosis</source><year>1994</year><volume>107</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">7945563</pub-id><pub-id pub-id-type="doi">10.1016/0021-9150(94)90145-7</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qui&#x000f1;ones Galvan</surname><given-names>A</given-names></name><name><surname>Muscelli</surname><given-names>E</given-names></name><name><surname>Catalano</surname><given-names>C</given-names></name><name><surname>Natali</surname><given-names>A</given-names></name><name><surname>Sanna</surname><given-names>G</given-names></name><name><surname>Masoni</surname><given-names>A</given-names></name><name><surname>Bernardini</surname><given-names>B</given-names></name><name><surname>Barsacchi</surname><given-names>R</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><article-title>Insulin decreases circulating vitamin E levels in humans</article-title><source>Metabolism</source><year>1996</year><volume>45</volume><fpage>998</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">8769359</pub-id><pub-id pub-id-type="doi">10.1016/S0026-0495(96)90270-X</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>MH</given-names></name><name><surname>Maehata</surname><given-names>E</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>A</given-names></name><name><surname>Murai</surname><given-names>F</given-names></name><name><surname>Mesaki</surname><given-names>N</given-names></name></person-group><article-title>The relationship between exercise-induced oxidative stress and the menstrual cycle</article-title><source>Eur J Appl Physiol</source><year>2004</year><volume>93</volume><fpage>82</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15243748</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O</surname><given-names>MH</given-names></name><name><surname>Maehata</surname><given-names>E</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>A</given-names></name><name><surname>Murai</surname><given-names>F</given-names></name><name><surname>Mesaki</surname><given-names>N</given-names></name></person-group><article-title>The relationship between exercise-induced oxidative stress and the menstrual cycle</article-title><source>Eur J Appl Physiol</source><year>2004</year><volume>93</volume><fpage>82</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15243748</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>R</given-names></name><name><surname>Venkata Madhu</surname><given-names>S</given-names></name><name><surname>Kaur Gambhir</surname><given-names>J</given-names></name><name><surname>Madhava Prabhu</surname><given-names>K</given-names></name></person-group><article-title>Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy</article-title><source>Clin Biochem</source><year>2003</year><volume>36</volume><fpage>557</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14563450</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9120(03)00094-8</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicotera</surname><given-names>TM</given-names></name><name><surname>Privalle</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>TC</given-names></name><name><surname>Oshimura</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name></person-group><article-title>Differential proliferative responses of Syrian hamster embryo fibroblasts to paraquat-generated superoxide radicals depending on tumor suppressor gene function</article-title><source>Cancer Res</source><year>1994</year><volume>15;54</volume><fpage>3884</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8033111</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murrell</surname><given-names>GA</given-names></name><name><surname>Francis</surname><given-names>MJ</given-names></name><name><surname>Bromley</surname><given-names>L</given-names></name></person-group><article-title>Modulation of fibroblast proliferation by oxygen free radicals</article-title><source>Biochem J</source><year>1990</year><volume>1;265</volume><fpage>659</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">2154966</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Randerath</surname><given-names>K</given-names></name><name><surname>Randerath</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>CV</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name></person-group><article-title>Structural origins of bulky oxidative DNA adducts (type II I-compounds) as deduced by oxidation of oligonucleotides of known sequence</article-title><source>Chem Res Toxicol</source><year>1996</year><volume>9</volume><fpage>247</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">8924599</pub-id><pub-id pub-id-type="doi">10.1021/tx950085v</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyokuni</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Yodoi</surname><given-names>J</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name></person-group><article-title>Persistent oxidative stress in cancer</article-title><source>FEBS Lett</source><year>1995</year><volume>16;358</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7821417</pub-id><pub-id pub-id-type="doi">10.1016/0014-5793(94)01368-B</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelicano</surname><given-names>H</given-names></name><name><surname>Carney</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name></person-group><article-title>ROS stress in cancer cells and therapeutic implications</article-title><source>Drug Resist Updat</source><year>2004</year><volume>7</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">15158766</pub-id><pub-id pub-id-type="doi">10.1016/j.drup.2004.01.004</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>JC</given-names></name><name><surname>Perrella</surname><given-names>MA</given-names></name><name><surname>Yoshizumi</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>CM</given-names></name><name><surname>Haber</surname><given-names>E</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>ME</given-names></name></person-group><article-title>Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>6369</fpage><lpage>6373</lpage><pub-id pub-id-type="pmid">8022789</pub-id><pub-id pub-id-type="doi">10.1073/pnas.91.14.6369</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>RA</given-names></name><name><surname>Applebaum-Bowden</surname><given-names>D</given-names></name><name><surname>Demers</surname><given-names>LM</given-names></name><name><surname>Bartholomew</surname><given-names>M</given-names></name><name><surname>Landis</surname><given-names>JR</given-names></name><name><surname>Hazzard</surname><given-names>WR</given-names></name><name><surname>Santen</surname><given-names>RJ</given-names></name></person-group><article-title>Lipoprotein lipids in women with androgen excess: independent associations with increased insulin andandrogen</article-title><source>Clin Chem</source><year>1990</year><volume>36</volume><fpage>283</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2406040</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexandraki</surname><given-names>K</given-names></name><name><surname>Protogerou</surname><given-names>AD</given-names></name><name><surname>Papaioannou</surname><given-names>TG</given-names></name><name><surname>Piperi</surname><given-names>C</given-names></name><name><surname>Mastorakos</surname><given-names>Gw</given-names></name><name><surname>Lekakis</surname><given-names>J</given-names></name><name><surname>Panidis</surname><given-names>D</given-names></name><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name></person-group><article-title>Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome</article-title><source>Hormones (Athens)</source><year>2006</year><volume>5</volume><fpage>126</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16807225</pub-id></citation></ref></ref-list></back></article> 